{"title":"在埃塞俄比亚，以多替格拉韦和依非韦伦为基础的抗逆转录病毒治疗的艾滋病毒感染者代谢综合征：一项比较横断面研究。","authors":"Mohammed Jemal, Baye Ashenef, Deresse Sinamaw, Adane Adugna, Mamaru Getinet, Temesgen Baylie, Nuredin Chura Waritu","doi":"10.1177/23259582241303305","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.</p><p><strong>Methods: </strong>A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.</p><p><strong>Results: </strong>The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (<i>P</i> = .019). Body mass index ≥ 25 kg/m<sup>2</sup> (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm<sup>3</sup> (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = .86; 95% CI: 1.14-7.20) were associated with metabolic syndrome.</p><p><strong>Conclusion: </strong>The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.</p>","PeriodicalId":17328,"journal":{"name":"Journal of the International Association of Providers of AIDS Care","volume":"23 ","pages":"23259582241303305"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635881/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.\",\"authors\":\"Mohammed Jemal, Baye Ashenef, Deresse Sinamaw, Adane Adugna, Mamaru Getinet, Temesgen Baylie, Nuredin Chura Waritu\",\"doi\":\"10.1177/23259582241303305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.</p><p><strong>Methods: </strong>A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.</p><p><strong>Results: </strong>The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (<i>P</i> = .019). Body mass index ≥ 25 kg/m<sup>2</sup> (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm<sup>3</sup> (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = .86; 95% CI: 1.14-7.20) were associated with metabolic syndrome.</p><p><strong>Conclusion: </strong>The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.</p>\",\"PeriodicalId\":17328,\"journal\":{\"name\":\"Journal of the International Association of Providers of AIDS Care\",\"volume\":\"23 \",\"pages\":\"23259582241303305\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635881/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the International Association of Providers of AIDS Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/23259582241303305\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International Association of Providers of AIDS Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23259582241303305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Metabolic Syndrome Among People Living With HIV on Dolutegravir and Efavirenz-Based Antiretroviral Therapy in Ethiopia: A Comparative Cross-Sectional Study.
Purpose: This study aimed to assess the burden of metabolic syndrome among people living with HIV (PLWH) on dolutegravir (DTG)- and efavirenz (EFV)-based regimens.
Methods: A hospital-based comparative cross-sectional study design was implemented from May 5, 2022, to August 5, 2022.
Results: The overall prevalence of metabolic syndrome was 18.6% (32/172) for all regimens, with 25.6% (22/86) for the DTG- and 11.6% (10/86) for the EFV-based regimens (P = .019). Body mass index ≥ 25 kg/m2 (adjusted odds ratio [AOR] = 3.04; 95% confidence interval [CI]: 1.13-8.14), CD4 count ≥ 500 cells/mm3 (AOR = 3.01; 95% CI: 1.09-8.28), insufficient physical activity (AOR = 2.60; 95% CI: 1.00-6.72), and DTG-based regimen (AOR = .86; 95% CI: 1.14-7.20) were associated with metabolic syndrome.
Conclusion: The prevalence of metabolic syndrome was significantly higher among PLWH on DTG-based regimens. This signifies that DTG-treated patients should be advised on lifestyle adjustments to prevent the development of metabolic syndrome.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
